Log In
BCIQ
Print this Print this
 

Exendin (9-39)

  Manage Alerts
Collapse Summary General Information
Company Stanford University
Description31-amino acid peptide that acts as a competitive antagonist of glucagon-like peptide-1 receptor (GLP-1R; GLP1R)
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor antagonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationHypoglycemia
Indication DetailsTreat hypoglycemia associated with gastric bariatric surgery
Regulatory Designation
PartnerEiger BioPharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/22/2016

Undisclosed

Undisclosed

Undisclosed

11/12/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today